Curzion Pharmaceuticals Acquired by Horizon Therapeutics

NEW YORK–LipoScience Inc. set terms for its initial public offering Thursday, with the diagnostics company looking to raise as much as $75 million and become the first health-care company to go public this year.

The company said in a filing with the Securities and Exchange Commission that it expects to fetch between $13 and $15 each for its five million shares.

The company develops medical diagnostic tests and analytics tools. Its key product measures low-density lipoprotein, or LDL, particles in blood. The particles can provide clues about heart disease.